25.43
0.27 (1.07%)
| Previous Close | 25.16 |
| Open | 24.82 |
| Volume | 23,602 |
| Avg. Volume (3M) | 718,378 |
| Market Cap | 1,657,444,096 |
| Price / Sales | 1.59 |
| Price / Book | 7.82 |
| 52 Weeks Range | |
| Earnings Date | 12 Nov 2026 |
| Operating Margin (TTM) | -373.30% |
| Diluted EPS (TTM) | -3.89 |
| Total Debt/Equity (MRQ) | 0.43% |
| Current Ratio (MRQ) | 6.47 |
| Operating Cash Flow (TTM) | -137.62 M |
| Levered Free Cash Flow (TTM) | -77.73 M |
| Return on Assets (TTM) | -56.70% |
| Return on Equity (TTM) | -115.47% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Zenas BioPharma, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -0.5 |
| Relative Valuation | NA |
| Financial Health | NA |
| AI Insight | NA |
| Weighted Average | -0.33 |
Select this tab to load the latest available analysis.
|
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The Company manages its operations on a consolidated basis as a single reportable segment focused on the research, development and commercialization of transformative immunology-based therapies. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 21.20% |
| % Held by Institutions | 74.88% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Royalty Pharma Sub-Manager, Llc | 30 Jun 2026 | 2,388,150 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |